Franjo Grotenhermen graduated in medicine and received his doctorate in Cologne. His fields of practice included internal medicine, surgery and naturopathy. He is head of the Centre for Cannabis Medicine in Steinheim (NRW) with a focus on therapy with cannabis and cannabinoids.
Grotenhermen is Executive Director of the Arbeitsgemeinschaft Cannabis als Medizin e.V. (ACM) (since 1997), Executive Director of the International Association for Cannabinoid Medicines (IACM) (since 2000) and author of the IACM Information, which appears fortnightly in several languages on the IACM website.
Grotenhermen is an employee of the Cologne-based nova Institute, co-owner of Endoxo GmbH (founded in 2019), a company that produces CBD and other hemp products. He is a lecturer at Dresden International University. He is Chief Medical Advisor of Telaleaf Health, an internet platform for telemedicine in the field of cannabis and cannabinoids. He is a member of the Scientific Advisory Board of the journals Cannabis and Cannabinoid Research, edited by Prof. Daniele Piomelli at Mary Ann Liebert Publishing, and of the Scientific Advisory Board of Medical Cannabis and Cannabinoids, edited by Prof. Rudolf Brenneisen at Karger Publishing. He is honorary president of the Union Francophone pour les Cannabinoïdes en Médecine (UFCM) as well as a member of the scientific advisory board of Portugal Medical Cannabis (PTMC).
He received the following awards: Hanf-Preis 1999 of Cannabusiness, IACM 2011 Special Award, ICBC 2018 Lifetime Achievement Award, Robert Newman Memorial Award 2018 of Akzept e.V., Honorary Award GFS-Award 2021 of Gemeinnützige Forschungsvereinigung Saluplanta e.V..